Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHART-AC: ctHPVDNA Adapted ChemoRadiation +/- Retifanlimab in Anal Cancer
NCT07425054Phase 2Recruiting
- Sponsor
- Jennifer Dorth
- Start
- Jun 2026
- Primary completion
- Jan 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retifanlimab in anal squamous cell carcinoma (SCCA), sponsored by Jennifer Dorth. Primary endpoint: Disease-Free Survival at 1 year. Started Jun 2026; status: recruiting.
02
Drugs
retifanlimab
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on NCT07425054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07425054.